IZERVAY (avacincaptad pegol sodium)
IZERVAY is indicated for the treatment of Geographic Atrophy; Age-Related Macular Degeneration.
How IZERVAY Works
Avacincaptad pegol is a PEGylated RNA aptamer that binds to and inhibits complement protein C5. By inhibiting C5, the drug prevents its cleavage into the effector molecules C5a and C5b, thereby decreasing the formation of the membrane attack complex (MAC).
Details
- Status
- Prescription
- First Approved
- 2023-08-04
- Patent Cliff
- 2034
- Routes
- INTRAVITREAL
- Dosage Forms
- SOLUTION
IZERVAY Approval History
What IZERVAY Treats
2 indicationsIZERVAY is approved for 2 conditions since its original approval in 2023. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Geographic Atrophy
- Age-Related Macular Degeneration
IZERVAY Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to IZERVAY
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
IZERVAY FDA Label Details
Indications & Usage
FDA Label (PDF)IZERVAY is indicated for the treatment of Geographic Atrophy; Age-Related Macular Degeneration.
IZERVAY Patents & Exclusivity
Patents (6 active)
Pro Intelligence Preview
Deep insights for IZERVAY
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2034
- • 6 active patents
Trial Analysis
- • Clinical trial tracking
- • Development stage analysis
Competitive Landscape
- • 2 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.